1. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile.
- Author
-
Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R, Cereceda-Solis K, Aguirre A, Travisany D, Palma-Vejares R, Barriga GP, Gaggero A, Martínez-Valdebenito C, Corre NL, Ferrés M, Balcells ME, Fernandez J, Ramírez E, Villarroel F, Valiente-Echeverría F, and Soto-Rifo R
- Subjects
- Amino Acid Substitution, Animals, Chile, Chlorocebus aethiops, Female, HEK293 Cells, Humans, Male, Vero Cells, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 blood, COVID-19 genetics, COVID-19 Serological Testing, Mutation, Missense, SARS-CoV-2 genetics, SARS-CoV-2 metabolism, Spike Glycoprotein, Coronavirus blood, Spike Glycoprotein, Coronavirus genetics
- Abstract
Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; thus, characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding of immunity at the local level. Given our inability to perform massive classical neutralization assays due to the scarce availability of BSL-3 facilities in the country, we developed and fully characterized an HIV-based SARS-CoV-2 pseudotype, which was used in a 96-well plate format to investigate NAb responses in samples from individuals exposed to SARS-CoV-2 or treated with convalescent plasma. We also identified samples with decreased or enhanced neutralization activity against the D614G spike variant compared with the wild type, indicating the relevance of this variant in host immunity. The data presented here represent the first insights into NAb responses in individuals from Chile, serving as a guide for future studies in the country., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
- Published
- 2021
- Full Text
- View/download PDF